Our PNA Intracellular Delivery Testing services help biotechnology companies, pharmaceutical discovery teams, and research institutions determine whether a peptide nucleic acid construct is merely associated with cells or is truly reaching the intracellular compartment where it must act. Because PNA combines a neutral polyamide backbone with strong sequence-specific hybridization to RNA and DNA, it is attractive for steric blocking, splice modulation, target validation, and intracellular probe development. In practice, however, cell entry, endosomal trapping, sequence-dependent solubility, and readout selection often become the limiting steps long before target biology can be interpreted with confidence.
Our platform integrates construct review, labeling and conjugation strategy support, cell-based uptake assays, localization analysis, endosomal escape assessment, and functional readout design so clients can make better decisions on PNA optimization. By connecting chemistry, delivery strategy, and assay design, we help teams build testing plans that reduce false positives, clarify intracellular behavior, and generate data that are useful for next-step delivery engineering or candidate prioritization.
Total Uptake Does Not Equal Productive Delivery: Many PNA programs show measurable cellular association by fluorescence, yet most of the material may remain bound to the membrane or trapped in endosomal compartments. We design testing workflows that separate gross uptake from intracellular localization and functional access so teams do not over-interpret a single signal.
Carrier Choice Cannot Be Copied Directly From Standard Oligo Workflows: The neutral PNA backbone changes how constructs interact with cationic lipids, peptides, and nanoparticle systems. Our studies compare fit-for-purpose approaches, including cell-penetrating peptide conjugation, lipid-enabled formats, and nanoparticle-associated delivery strategies, to identify the most practical route for a given construct.
Endosomal Entrapment Often Masks Construct Potential: PNA can enter cells through endocytic pathways but still fail to reach the cytosol or nucleus in a productive form. We build testing plans around trafficking and release questions, using imaging, compatible reporter concepts, and functional assays to determine whether endosomal escape is the dominant bottleneck.
Labeling and Formulation Can Distort the Biology: A fluorophore, lipid, PEG chain, or peptide can improve detectability but also alter solubility, aggregation behavior, or uptake route. Our team helps clients compare labeled and unlabeled constructs, evaluate formulation controls, and decide when support from our broader drug delivery system services is needed for a more representative test article.
Different Cell Models Produce Different Delivery Stories: Adherent versus suspension cells, rapidly dividing versus slow-growing cells, and nuclear versus cytosolic targets can change the apparent success of a PNA construct. We align assay windows, controls, and dose/time-course design with the biological question so the resulting data are more relevant to the client's real project decisions.
This service is designed for teams that already have a PNA concept, a candidate series, or a conjugated construct and need structured evidence of intracellular performance. We support early screening, delivery troubleshooting, and comparative studies across unmodified PNA, labeled PNA, CPP-PNA conjugates, lipid-associated constructs, and other delivery-enabled formats.
Rather than treating delivery as a single assay, we build modular testing plans that connect chemistry review, cell exposure strategy, uptake analysis, trafficking interpretation, and target-relevant functional evaluation.
The most useful PNA delivery studies combine orthogonal readouts. This matrix shows how different assay layers answer different questions so clients can choose a testing package that matches their decision point rather than relying on a single measurement.
| Testing Objective | Typical Readout | What It Clarifies | Common Risk if Used Alone | Best Use in a PNA Program |
| Total cellular association | Fluorescence quantification by flow cytometry or plate-based signal analysis | Whether the construct interacts with and enters the cell population at a measurable level | Can overestimate productive delivery because surface binding and trapped vesicles may dominate the signal | Early ranking of candidates, carriers, and dosing windows |
| Internalization confirmation | Surface quench controls, wash protocols, or matched membrane-binding controls | Whether signal comes from internalized material rather than extracellular or membrane-associated PNA | Does not show the final intracellular compartment reached by the construct | Validation of uptake claims before deeper localization work |
| Intracellular localization | Confocal or high-content imaging with organelle markers | Whether PNA remains punctate in vesicles, redistributes in the cytosol, or reaches the perinuclear or nuclear region | Imaging alone may remain descriptive without demonstrating biological productivity | Mechanistic troubleshooting and carrier comparison |
| Endosomal escape tendency | Escape-oriented imaging panels, marker co-localization shifts, or compatible reporter-based systems | Whether endosomal release is likely to be the major bottleneck after entry | Method selection must match the construct and cell model to avoid over-interpretation | Prioritizing release-enhancing chemistry or formulation strategies |
| Functional intracellular activity | Splice-switching reporter, RT-PCR, RT-qPCR, or target-dependent downstream readout | Whether delivered PNA reaches the compartment required for sequence-specific action | Negative results can reflect weak target biology, insufficient exposure, or poor assay design rather than failed uptake alone | Lead confirmation and delivery strategy selection |
| Assay fitness and tolerability | Viability, morphology, and exposure-condition controls | Whether the apparent delivery gain is compatible with acceptable cell health and usable assay conditions | Delivery performance can be overstated if toxicity is not monitored in parallel | Selecting realistic working concentrations and formulation conditions |
Different PNA delivery formats fail for different reasons. The table below helps clients match the testing package to the chemistry and barrier profile of the construct under evaluation.
| PNA Format or Delivery Concept | Main Strength | Main Limitation | Testing Priorities | Typical Program Fit |
| Unmodified PNA | Preserves native construct properties and target-binding design | Frequently shows weak spontaneous uptake in mammalian cell systems | Baseline uptake, localization, and benchmark comparison against enabled formats | Establishing whether delivery engineering is required at all |
| Fluorescently labeled PNA | Supports direct visualization and rapid screening | Label placement can alter behavior and may not reflect unlabeled activity | Internalization controls, localization imaging, and label-bias comparison | Early mechanistic mapping and assay setup |
| CPP-PNA conjugate | Can improve cellular entry and change intracellular trafficking profile | Performance depends strongly on peptide sequence, linker design, and endosomal release | Uptake quantification, trafficking analysis, and functional confirmation | Steric-blocking and intracellular target-access studies |
| Lipid-associated or lipid-conjugated PNA | May improve membrane interaction and delivery efficiency | Can introduce aggregation, serum sensitivity, or formulation-dependent variability | Formulation screening, time-course uptake, and viability-balanced optimization | Comparative cell-line screening and delivery troubleshooting |
| Nanoparticle or polymer-enabled PNA | Offers broader engineering flexibility for uptake and release tuning | More variables must be controlled, including particle behavior and cargo release | Carrier comparison, intracellular localization, and functional output correlation | Multi-parameter delivery development programs |
| Multifunctional PNA construct | Allows combination of targeting, imaging, shielding, or release-enabling elements | Higher complexity can reduce manufacturability and make assay interpretation harder | Stepwise testing of each design element plus integrated construct validation | Advanced optimization and custom delivery concept evaluation |
Our workflow is built to move from a clear delivery question to interpretable data. Each stage is designed to help clients understand not only whether PNA enters cells, but also why a construct succeeds or fails under the chosen experimental conditions.
We review the PNA sequence, target type, construct format, preferred cell model, and intended biological endpoint. This step clarifies whether the main question is entry, localization, release, functional activity, or comparison of multiple delivery concepts.
Our team evaluates labeling needs, control design, exposure conditions, and any risks linked to aggregation, solubility, or assay interference. The result is a fit-for-purpose test plan with prioritized readouts and acceptance criteria.
Client-supplied or internally prepared constructs are checked for identity, handling behavior, and readiness for cell-based work. When needed, we coordinate conjugation, fluorescent tagging, purification, or matched comparator preparation before screening starts.
We execute the agreed study design across selected doses, time points, serum conditions, or carrier systems. Initial output focuses on uptake level, cell population distribution, and the basic question of whether the construct is entering cells in a measurable manner.
Deeper studies examine where the PNA goes after entry and whether it reaches the compartment required for activity. Imaging, trafficking analysis, and target-relevant readouts are integrated to distinguish trapped constructs from productive intracellular delivery.
Final reporting links chemistry, delivery format, assay outcome, and practical next steps. Clients receive a structured interpretation of whether the next move should be carrier optimization, construct redesign, control refinement, or progression into broader delivery development.
PNA delivery questions are rarely solved by a single assay. Our platform is built to generate decision-grade data by connecting sequence chemistry, delivery strategy, and intracellular readout design within one coordinated study framework.
We support cell-based PNA programs where intracellular access is a make-or-break variable. The service can be adapted to discovery-stage screening, construct troubleshooting, and deeper mechanistic analysis across multiple delivery concepts.
If your team needs to determine whether a PNA construct truly reaches the intracellular compartment required for activity, our testing platform can help you generate clearer answers. We support study design, construct preparation strategy, uptake analysis, trafficking assessment, functional readout planning, and interpretation for research-stage PNA programs. Whether you are comparing CPP-PNA constructs, evaluating a labeled probe, screening formulation options, or troubleshooting endosomal trapping, we provide a practical path to data that can guide the next design decision. Contact us to discuss your PNA intracellular delivery testing needs.
It measures how a PNA construct behaves after cell exposure, including total uptake, internalization, intracellular localization, endosomal trapping or escape, and target-relevant functional activity.
A strong uptake signal can still reflect membrane binding or vesicular trapping. Productive delivery requires the PNA to reach the compartment where its target is located.
Yes. Labeled constructs are useful for uptake and localization studies, while unlabeled comparators help confirm that the label itself is not changing delivery behavior.
Depending on project scope, studies can compare free PNA, CPP-PNA conjugates, lipid-associated constructs, nanoparticle-enabled formats, and other custom delivery concepts.
The approach depends on the construct and cell model. It may include trafficking-focused imaging, co-localization shifts, compatible reporter systems, and functional readouts that indicate whether release is occurring after uptake.
